Interesting to see where ADCs will go in neoadjuvant TNBC.

4 cycles sacituzumab=pCR rate 30%

4 cycles Dato-Dxd + Durva = pCR rate ?

How can these compete with Keynote 522= pCR rate >60%

Important to explore new ADCs. Also critical to understand how ADCs currently perform in our pts. At ASCO24, we will present the largest RW cohort to date of pts receiving T-DXd for MBC, including for HER2-0 MBC & after SG. Collaboration Dana-Farber Yale University. meetings.asco.org/abstracts-pres…

Also, at #ASCO24 the long awaited #postmonarch trial (to extend or not to extend—that is the question) and more detail on how we may incorporate ctDNA into personalized care Kevin Kalinsky, MD, MS Sherene Loi, MD

Fantastic time in the beautiful Santiago, Chile presenting at the Simposio International Cancer de Mama with Aleix Prat #PrecisionOncology Paolo Tarantino!

20 minutes on Post-CDK4/6 Landscape was a challenge 😊

Here we are with Dr Sarah Sammons from Dana-Farber’s Breast Oncology Center

simposiocancerdemama.cl

Estate planning can be overwhelming and can often bring up topics that are difficult to discuss. However, being prepared can also bring a sense of comfort.

Join this webinar from Triage Cancer to learn more about estate planning. Register here: mbca.me/4cYCg9h

The #FDA approval of Enhertu for patients with HER2-positive solid tumors is an “unprecedented approval,” Dr. Sarah Sammons (Dr Sarah Sammons) of Dana-Farber @dfci_breastonc told CURE®.

Read more about this treatment option: curetoday.com/view/enhertu-m…

Ongoing clinical trials testing the activity of ADCs in patients with brain metastases or LMD.

Hope to see even more inclusion in clinical trials moving forward - not only in breast cancer, but in other solid tumors as well!

My colleague Katrine Whiteson is launching a new, exciting, fully virtual, study for breast cancer survivors 1 year post treatment studying how a high fiber diet can impact gut microbiome. Please visit docs.google.com/document/d/1Gp… to learn more.

Excellent and important paper we cannot extrapolate all trial data to the general cancer population

This is common sense to me.

I do feel like smart phones have contributed to medical burnout in a major way.

I would love to do a trial with an intervention of old school pagers and paper charts versus EMR and smart phones and see how burnout reduces dramatically.

But also, intracranial response rates over 30% for both ADCs which brings so much hope for an entire drug class for the treatment of CNS metastases!

oprahdaily.com/about/a6011259…

How can we improve quality of life for people living with breast cancer brain metastasis or leptomeningeal disease? This one-stop resource hub for BCBM offers education, community, and info on clinical trials.

SEE WHAT'S NEW: MBCAlliance.org/BrainMets24
@SHAREing

T-DXd is the premier ADC for the treatment of pts with HER2+ MBC BrMs.

The analysis underscores the pressing need to investigate T-DXd in HER2-low BrMs, active HER2+ BrMs across solid tumors, and LMD.
We suggest default inclusion of pts with BrMs into clinical trials of ADCs.

Antibody–drug conjugates are active in patients with HER2+ breast cancer brain metastases: where do we go from here? Read the editorial on the brain mets analysis from DB03 by Sarah Sammons (Dr Sarah Sammons) and Nancy Lin (@nlinmd) from Dana-Farber’s Breast Oncology Center. esmoopen.com/article/S2059-…

very happy to be there with friends and colleagues! join us 👇👇👇

These sort of reports are losing their novelty quickly. AI can probably do most tests/reports as well as average specialists in most fields. That is not the question. The question is: how can we use it to make healthcare better, and to make doctoring more humane and useful.